I noticed that Reuters story has been corrected on the Biomeds reports site (but not in the Reuters story) regarding the comparison with other pain meds
http://www.biomedreports.com/2012062097745/qrx-pharma-a-high-stakes-gamble-in-the-fdas-upcoming-decision.html